BioNTech
NEWS
Importantly, the researchers recovered virus that they were able to culture, indicating a high risk for transmissibility.
A flurry of COVID-19 research news came out today. Here’s a look.
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
The FDA has a massive backlog of site inspections due to the pandemic. To address the problem, the agency made its Resiliency Roadmap outlining its priorities.
Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
Researchers at John Hopkins made their preliminary conclusions that the vaccines produced by Pfizer-BioNTech and Moderna did not cause the hearing loss.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Thermo Fisher and the University of California partnered with the development and manufacturing of cell-based therapies with the construction of its 44,000 sq. ft. manufacturing facility.
JOBS
IN THE PRESS